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Whilst kidney transplantation is the treatment of choice for suitable patients with end-
stage kidney disease, approximately 25% of chronic kidney disease (CKD) patients 
have peripheral arterial disease (PAD)1. CT angiography (CTA) can identify patients 
requiring revascularization procedures before transplant listing, however its use has 
been limited because of the risk of nephrotoxicity in patients with residual renal 
function. Ferumoxytol (Feraheme®, AMAG Pharmaceuticals, Waltham, MA, USA) is 
an iron oxide nanoparticle used for treatment of iron deficiency anaemia that has 
superparamagnetic properties with high r1 relaxivity and a long intravascular half-life. 
We compared ferumoxytol-enhanced MRA (FeMRA) with CTA in assessment of 
potential kidney transplant recipients using anatomical and signal parameters as 
surrogates of diagnostic quality.  
 We prospectively enrolled 36 patients (54±11 years; 61% male; 47% with 
diabetic nephropathy) who had FeMRA and CTA of aortoiliac vasculature on the 
same day. The study was approved by the institutional review board (North of 
Scotland Research Ethics Committee reference: 16/NS/0099). CTA was performed 
with a 320-detector row CT scanner (Canon/Toshiba, Aquilion One Vision edition; 
USA) after injection of 100cc of iodine contrast (Omnipaque 350). MRI studies were 
performed on a 3.0T Prisma MRI scanner (Magnetom, Siemens Healthineers, 
Erlangen; Germany) after infusion of 3mg/kg of ferumoxytol based on data from a 
dose-finding study2. For detection of arterial calcification, a specific MRI sequence 
[three-dimensional (3D) free-breathing (StarVIBE) fast low-angle shot (FLASH)] was 
performed before ferumoxytol administration.  
 CTA and FeMRA images were synchronized using anatomical landmarks and 
prespecified arterial and venous cross-sections (overall 216) were selected for 
comparative analysis. Regions of interest (ROI) were used for the infra-renal 
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abdominal aorta, right common iliac artery, right external iliac artery, inferior vena 
cava, right common iliac vein and right external iliac vein to estimate the a) arterial 
diameter, b) vein diameter, c) area of calcification and d) luminal enhancement 
(Figure 1). Two independent readers assessed the FeMRA (new technique) and a 
third reader the CTA (standard technique). Interclass correlation coefficients (ICC) 
with 95% confidence intervals (95% CI) were performed to test intra- and inter-
reader consistency of agreement and mean differences (and 95% CI) were 
estimated. 
There was excellent inter-reader agreement in assessment of the FeMRA across 
all vascular sections. ICC were 0.88 – 0.92 for the arterial diameter, 0.79 – 0.89 for 
the vein diameter, 0.88 – 0.91 for the area of calcification and 0.92 – 0.97 for the 
contrast-to-noise ratio (CNR). Among 12 patients that were selected at random for 
intra-reader agreement, ICC were between 0.79 – 0.99 for all parameters, indicating 
excellent agreement. Comparison of FeMRA with CTA showed no significant 
difference in arterial diameter and area of calcification (mean differences -0.36 – 
0.89mm and -0.05 – 0.06mm2, respectively), but there was significant systematic 
difference in vein diameter (mean difference 1.53 – 2.44mm). CNR values were 
significantly higher in FeMRA in both the arterial and venous vasculature (mean 
differences 3.16 – 7.44 and 16.78 – 24.70, respectively).  
We have demonstrated an MR imaging strategy for kidney transplant candidates, 
which provides reliable depiction of arterial lumen, accurate detection of arterial 
calcification and synchronous delineation of the venous vasculature. In addition, the 
favorable pharmacokinetics of ferumoxytol allow imaging of predialysis patients 
without concerns for iodine or gadolinium contrast toxicity. From a clinical standpoint, 
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FeMRA can complement or even replace currently used imaging methods in 
pretransplant assessment of CKD patients with known or suspected PAD.  
Our study has limitations. Arterial-phase CTA combined with CT venography was 
not performed but this requires higher doses of iodine contrast, venous opacification 
can be suboptimal, and acquisition times vary considerably. This limits conclusions 
that can be drawn about venous anatomy in this study to some degree. In the steady 
state, ferumoxytol enhances arteries and veins equally and independently of bolus 
timing, however this attribute did not compromise diagnosis, as the arteries and 
veins of the abdomen and pelvis were readily distinguishable. Ferumoxytol is not 
currently licensed as a contrast agent for MRI and its commercial price 
(approximately $700 per 17mL vial) is not realistic for a routine deployment, limiting 
translation of our study protocol to clinical practice. However, its applicability in 
predialysis patients fills unmet clinical needs offering a safe and robust technique 
decisive to timely transplant listing. 
 5 
 
Figure 1. Method for the comparative analysis using arterial and venous cross-
sections. Panel A. Arterial cross-sections at the level of infra-renal abdominal aorta 
(AA), right common iliac artery (RCIA) and right external iliac artery (REIA) used for 
comparisons between CTA and StarVIBE/FeMRA. Note the consistency in the 
presence and conformity of calcifications between CTA and StarVIBE and the 
intraluminal filling defects in FeMRA, which correspond to calcified plaques. Panel B. 
Venous cross-sections at the level of inferior vena cava (IVC), right common iliac 
vein (RCIV) and right external iliac vein (REIV) used for comparisons between CTA 
and FeMRA 
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